ResMed Inc. (RMD) financial statements and ratios from SEC XBRL: revenue $5.65B (TTM), net margin 26.9%, revenue growth 9.9% YoY, P/E 21.9. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $5.65B |
| Net Margin | 26.9% |
| Revenue Growth (YoY) | 9.9% |
| EPS Growth (YoY) | 9.6% |
| FCF Growth (YoY) | -0.7% |
| P/E Ratio | 21.9 |
| EV / EBITDA | 15.6 |
| Price / Book | 5.01 |
| Price / Sales | 6.01 |
| FCF Yield | 10.7% |
| DCF Value (model) | $201.43 |
| DCF Upside vs Price | -11.8% |
| Altman Z-Score | 11.16 (safe) |
| Piotroski F-Score | 7/9 |
| Sector P/E (Healthcare) | 21.6 |
RMD overview · RMD earnings · RMD KPIs · RMD investor relations · RMD ownership · RMD peers · RMD filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.